Mesoblast (ASX:MSB) Asset Impairment Charge: A$0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
40 GF Score
Price A$2.36
! 2 Warning Signs
View Full Analysis

What is Mesoblast Asset Impairment Charge?

Mesoblast ASX:MSB -4.07% 40 Asset Impairment Charge is A$0.0 Mil as of Jun. 2026. GuruFocus rates ASX:MSB with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

Mesoblast's Asset Impairment Charge for the three months ended in Jun. 2026 was A$0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.0 Mil.

Mesoblast Asset Impairment Charge Related Terms

Mesoblast Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Mesoblast's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Asset Impairment Charge Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:MSB
40GF Score
Mesoblast Ltd ASX:MSB
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.0 Mil.

What does a Asset Impairment Charge of A$0.0 Mil mean?
Mesoblast (ASX:MSB) has a Asset Impairment Charge of A$0.0 Mil as of Jun. 2026.
Is Mesoblast's Asset Impairment Charge too high?
Mesoblast's current Asset Impairment Charge is A$0.0 Mil. Overall, Mesoblast has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Asset Impairment Charge compare to VRTX and REGN?
Mesoblast's Asset Impairment Charge of A$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Mesoblast's current Asset Impairment Charge is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Asset Impairment Charge of A$0.0 Mil. The current Asset Impairment Charge is A$0.0 Mil. Mesoblast's overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Asset Impairment Charge is A$0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
40GF Score

Get the complete analysis for ASX:MSB

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.36
Price